Impression

1. Progress of the metastatic burden of the skeleton with new highly PSMAexpressing osseous lesions disseminated in the skeleton and progress of the known bone secondaries.

2. Stability of the vital PSMA-expressing prostatic malignancy extended to the left seminal vesicle.

3. Progressive supra- and infradiaphragmatic LN secondaries with high PSMAexpression.

4. Patient primarily eligible for 177LuPSMA, should this be considered.

With kind regards,

Prof. Dr. Alexis Vrachimis, MD, PhD

Director of Nuclear Medicine

Dr. Ioannis Tsechelidis

Nuclear Medicine Physician